Under FDA Green Lights: Niche Biotechs and Specialty Financials Stage Quiet ComebacksGlobal Report·Oct 7, 2026 at 10:13 AMCAUD+100.00%NKTX+1.35%
Nkarta (NASDAQ:NKTX) Stock Price Down 3.5% - Here's What HappenedMarket Beat·Sep 26, 2026 at 05:00 AMNKTX+1.35%
H.C. Wainwright Reaffirms Their Buy Rating on Nkarta (NKTX)Tip Ranks·Sep 22, 2026 at 09:45 AMNKTX+1.35%
Nkarta to join H.C. Wainwright Global Investment Conference fireside chatPUBT·Sep 10, 2026 at 11:06 AMNKTX+1.35%
Nkarta to present initial Phase 1/2 autoimmune data for CAR-NK therapy NKX019 at ACR Convergence 2026PUBT·Sep 8, 2026 at 11:01 AMNKTX+1.35%
Mizuho Securities Sticks to Their Buy Rating for Nkarta (NKTX)Tip Ranks·Aug 17, 2026 at 04:15 PMNKTX+1.35%
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights | NKTX Stock NewsStockTitan·Aug 10, 2026 at 12:24 PMNKTX+1.35%
Divestitures and Capacity Rollouts Dictate Strategy Across US Niche EquitiesGlobal Report·Jul 28, 2026 at 09:13 AMSTDN+1.48%CIX-0.56%
